― FTX-6058 granted Fast Track Designation for sickle cell disease (SCD) from FDA in December 2022 ―― Completed enrollment in 6 mg and 2 mg dose cohorts of the Phase 1b trial of FTX-6058 in…
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with…
– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease –– Losmapimod is an oral small molecule that has the potential to be the first therapy to…
- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint - Supports proof-of-concept that FTX-6058 is a novel…
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development -Data will include initial HbF changes, safety, tolerability, pharmacokinetics, and other pharmacodynamic …
Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3 REACH trial Live webcast March 24, 2022 at 10:00am ET CAMBRIDGE, Mass., March 17, 2022 (GLOBE…
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with…